Abbott: defining risks and growth rates; creating a digestible acquisition target
This article was originally published in Scrip
Executive Summary
By announcing plans that it will split its existing activities into a diversified medical products company and a specialised branded pharmaceutical company, Abbott unveiled a strategy that separates low-risk business segments from the high-risk business of branded pharmaceuticals. The approach may also make the branded pharma branch a cleaner, more manageable acquisition target.